Amylin Replacement in Type 1 Diabetes

Amylin and Diabetes

63% glucagon reduction

Pramlintide reduced meal-stimulated glucagon area under the curve by 63% in type 1 diabetes patients, addressing a hormonal gap that insulin alone cannot fix.

Galderisi et al., JCEM, 2018

Galderisi et al., JCEM, 2018

View as image

Insulin therapy replaced half of what type 1 diabetes takes away. The autoimmune destruction of pancreatic beta cells eliminates production of two hormones, not one: insulin and amylin. For over a century, diabetes treatment focused exclusively on replacing insulin. Amylin, a 37-amino-acid peptide co-secreted with insulin from the same beta cell granules, was left out of the equation entirely.^[1] That gap has consequences. Without amylin, postprandial glucagon secretion goes unchecked, gastric emptying proceeds too fast, and glucose spikes after meals become difficult to control even with optimized insulin dosing. If you want the full picture of what amylin does and why it matters, start with the pillar article. This piece covers the specific biological case for replacing amylin in type 1 diabetes and what clinical trials have demonstrated.

The missing hormone: why insulin alone is not enough

In a healthy pancreas, beta cells release insulin and amylin together in a fixed ratio of roughly 100:1 after every meal. When type 1 diabetes destroys beta cells, both hormones disappear. By the time of diagnosis, amylin secretion is undetectable. As Kruger and colleagues described in 1999, the clinical implications of this dual deficiency had been overlooked for decades.^[2]

Amylin performs three functions that insulin does not:

Glucagon suppression. After a meal, glucagon secretion from pancreatic alpha cells should decrease to prevent the liver from dumping glucose while new glucose is arriving from food. Amylin suppresses this postprandial glucagon release. Without amylin, glucagon remains elevated after meals, adding an extra wave of hepatic glucose output on top of the carbohydrates being digested. This is a major contributor to postprandial hyperglycemia in type 1 diabetes.^[3]

Gastric emptying regulation. Amylin slows the rate at which food leaves the stomach and enters the small intestine. This creates a more gradual influx of glucose into the bloodstream, making it easier for insulin to match the rate of glucose appearance. Without amylin, gastric emptying is faster than it should be, and glucose arrives in the bloodstream faster than mealtime insulin can act.^[1]

Satiety signaling. Amylin activates neurons in the area postrema of the brainstem that promote the feeling of fullness after eating. Boyle and colleagues showed in 2018 that amylin reduces food intake through both homeostatic and hedonic pathways.^[4] The absence of this satiety signal in type 1 diabetes may partly explain why some patients gain weight on intensive insulin therapy.

Insulin therapy addresses glucose disposal but does nothing about any of these three mechanisms. This is the biological rationale for amylin replacement: it targets the parts of glucose regulation that insulin cannot reach.

What the clinical trials show

Pramlintide improves glycemic control and reduces glucagon

Nyholm and colleagues published one of the earliest controlled studies of pramlintide in type 1 diabetes in 1999. Pramlintide improved glycemic control and reduced postprandial glucagon concentrations in patients already on insulin.^[3] This was the first demonstration that replacing the missing amylin signal could correct a specific pathophysiological defect of type 1 diabetes.

Galderisi and colleagues provided the most precise quantification in 2018: pramlintide reduced meal-stimulated glucagon area under the curve by 63% (from 1,988 to 737 pg/mL/min, p<0.001) and the peak glucagon response by 71% in type 1 diabetes patients after 3-4 weeks of treatment.^[5] In the same study, liraglutide (a GLP-1 agonist) did not suppress meal-stimulated glucagon in these patients. This finding is important because it demonstrates that amylin and GLP-1 have distinct mechanisms of action on postprandial glucagon: amylin suppresses it directly through area postrema neurons, while GLP-1 does not achieve the same effect in type 1 diabetes.

Reduced glucose fluctuations on insulin pumps

Levetan and colleagues studied pramlintide in type 1 diabetes patients using insulin pumps in 2003. Adding pramlintide reduced 24-hour glucose fluctuations and specifically lowered postprandial excursions of glucose, glucagon, and triglycerides.^[6] The triglyceride finding is noteworthy: postprandial lipid spikes contribute to cardiovascular risk, and reducing them is a benefit that goes beyond glucose numbers.

One-year outcomes: HbA1c and weight

The most robust long-term data comes from Ratner and colleagues, who published a 1-year randomized controlled trial of pramlintide in 480 type 1 diabetes patients in 2004. Pramlintide (60 mcg, three times daily) plus insulin reduced HbA1c by 0.29-0.34% from baseline at 52 weeks, compared to 0.04% with placebo plus insulin.^[7]

The weight data may be more clinically meaningful than the HbA1c reduction. Patients on pramlintide lost an average of 1.3 kg over the year, while patients on insulin plus placebo gained weight. In type 1 diabetes, where intensive insulin therapy frequently causes weight gain, any treatment that improves glycemic control without adding weight is filling an unmet need.

Pramlintide in closed-loop insulin systems

Sherr and colleagues tested pramlintide as an adjunct to closed-loop (artificial pancreas) insulin delivery in 2016. Adding pramlintide delayed peak postprandial glucose and reduced glucose excursions, improving the performance of the closed-loop algorithm.^[8] Renukuntla and colleagues found similar results comparing pramlintide to a GLP-1 analog in a closed-loop setting, with pramlintide providing better postprandial glucose control.^[9]

This line of research is relevant because closed-loop insulin delivery is the direction of type 1 diabetes management. If these systems work better with amylin replacement, it strengthens the case for making amylin therapy part of the standard approach.

The combination question: amylin + GLP-1 in type 1 diabetes

Wong and colleagues reported three case studies in 2023 of type 1 diabetes patients with obesity treated with both pramlintide and a GLP-1 receptor agonist. The results were striking: one patient lost 20.9 kg (16.1% of body weight) over 10 months on semaglutide plus pramlintide.^[10] This combination addresses both the amylin deficiency inherent to type 1 diabetes and the appetite-suppressing effects of GLP-1 agonism.

This approach is still in the case-report stage and lacks randomized trial data. But it highlights a logical extension of amylin replacement: if type 1 diabetes patients are missing amylin and can also benefit from GLP-1 agonism, combining both may address glucose control, weight, and cardiovascular risk simultaneously. The success of amylin + GLP-1 combinations in the obesity space provides indirect support for this approach.

Why pramlintide failed commercially despite working

Pramlintide (brand name Symlin) was FDA-approved in 2005 for type 1 and type 2 diabetes. Despite clear clinical evidence, it never gained widespread adoption. The reasons illuminate what future amylin therapies need to overcome.

Dosing burden. Pramlintide required injection before every meal, three times daily, on top of existing insulin injections. For type 1 diabetes patients already managing multiple daily injections or pump changes, adding three more was a hard sell.

Hypoglycemia risk. Pramlintide slows glucose appearance from food. If patients did not reduce their mealtime insulin dose when starting pramlintide, the mismatch between insulin action and glucose absorption could cause hypoglycemia. This required careful dose titration that many clinicians found difficult to manage.

Nausea. Gastrointestinal side effects, particularly nausea, occurred frequently during the first weeks of treatment. While usually transient, the initial experience was enough to drive discontinuation in patients who were already managing a complex disease.

Modest HbA1c improvement. A 0.3% HbA1c reduction is real but small. For clinicians evaluating whether to add complexity to a type 1 diabetes regimen, this was often deemed insufficient to justify the burden.

None of these issues invalidate the biological rationale for amylin replacement. They reveal a delivery problem, not an efficacy problem. If amylin can be delivered in a way that eliminates the dosing burden and improves the side effect profile, the underlying science still supports its use. For a deeper look at pramlintide's full story, see the dedicated article on how pramlintide complements insulin.

Next-generation amylin analogs change the equation

The development of cagrilintide by Kruse and colleagues at Novo Nordisk addressed pramlintide's two core limitations: short half-life and amyloid aggregation risk. By attaching a fatty acid chain (lipidation) that binds albumin in the bloodstream, cagrilintide achieves a half-life of roughly 7 days, enabling once-weekly dosing.^[11]

Cagrilintide is currently being developed for obesity in combination with semaglutide (as CagriSema), not specifically for type 1 diabetes glucose control. But the technology it represents, a long-acting amylin analog compatible with weekly dosing, is directly applicable to the type 1 diabetes use case.

Other long-acting amylin analogs are in development. Volcansek and colleagues reviewed the current landscape in 2025, noting that second-generation non-aggregating amylin analogs with extended half-lives are advancing through clinical development for both obesity and diabetes indications.^[12] Zealand Pharma's petrelintide entered phase 2b trials in late 2024 for obesity, with plans to evaluate combination therapy with GLP-1 agonists.

For type 1 diabetes specifically, the ideal product would be a once-weekly amylin analog that could be added to existing insulin regimens without requiring mealtime dose adjustment. Whether any company pursues this indication depends on commercial calculations: type 1 diabetes is a smaller market than obesity or type 2 diabetes, but the biological rationale is arguably strongest in type 1, where amylin deficiency is absolute rather than relative.

What we still do not know

The biological case for amylin replacement in type 1 diabetes is strong. The practical case has gaps.

No long-acting amylin data in type 1 diabetes. All controlled trial data in type 1 diabetes used pramlintide, a short-acting analog. Whether cagrilintide or other long-acting analogs produce the same postprandial glucagon suppression and gastric emptying effects is unproven. The continuous versus pulsatile nature of amylin delivery may matter for physiological response.

No large combination trials. The Wong case series of pramlintide + GLP-1 agonists in type 1 diabetes included only three patients. Randomized trials are needed to establish efficacy and safety of this combination in the type 1 population specifically. The off-label use of GLP-1 drugs in type 1 diabetes is growing, but evidence remains thin.

Closed-loop integration. While early studies show pramlintide improves closed-loop performance, integrating an amylin analog into automated insulin delivery algorithms requires new software development and clinical validation. The algorithms need to account for slower gastric emptying when predicting insulin requirements.

Cardiovascular outcomes. No dedicated cardiovascular outcomes trial has tested amylin replacement in type 1 diabetes. The postprandial triglyceride reduction observed by Levetan suggests potential cardiovascular benefit, but this hypothesis requires prospective testing.

Pediatric data. Type 1 diabetes often presents in childhood. Pramlintide data in adolescents is limited, and no long-acting amylin analog has been tested in children. Growth, development, and appetite regulation create a different risk-benefit calculation in younger populations.

The Bottom Line

Type 1 diabetes destroys the beta cells that produce both insulin and amylin, creating a dual hormone deficiency that insulin therapy alone cannot fully correct. Pramlintide, the only approved amylin analog, has demonstrated glucagon suppression, reduced postprandial glucose fluctuations, modest HbA1c improvement, and weight neutrality in clinical trials spanning up to one year. Its commercial failure was driven by dosing burden, not lack of efficacy. Next-generation long-acting amylin analogs like cagrilintide have solved the half-life problem, but none have been tested in type 1 diabetes specifically. The biological rationale for amylin replacement in type 1 diabetes is well-established; the delivery technology is now catching up.

Frequently Asked Questions

Why do people with type 1 diabetes have no amylin?

Amylin is produced by the same pancreatic beta cells that produce insulin. When the immune system destroys these cells in type 1 diabetes, both hormones are lost. By the time of diagnosis, amylin secretion is typically undetectable. This creates a dual deficiency that insulin therapy alone does not fully address.

Does pramlintide work for type 1 diabetes?

Pramlintide has demonstrated measurable benefits in type 1 diabetes clinical trials. A 1-year study by Ratner and colleagues showed HbA1c reductions of 0.29-0.34% and weight loss of 1.3 kg compared to insulin alone. It also reduced postprandial glucagon by up to 63% and lowered glucose fluctuations in patients on insulin pumps.

What does amylin do that insulin cannot?

Amylin performs three functions beyond insulin's scope: it suppresses postprandial glucagon secretion from the liver, slows gastric emptying so glucose enters the bloodstream more gradually, and activates satiety centers in the brainstem to reduce food intake. Insulin handles glucose disposal into cells but does not influence any of these three mechanisms.

Why did pramlintide fail commercially?

Pramlintide required three daily injections before meals, on top of existing insulin injections. It caused nausea during initial weeks and required careful insulin dose adjustment to avoid hypoglycemia. The HbA1c improvement (roughly 0.3%) was modest. These practical barriers limited adoption despite the drug's proven mechanism of action.

Are there long-acting amylin drugs for type 1 diabetes?

No long-acting amylin analog is currently approved or in clinical trials specifically for type 1 diabetes. Cagrilintide, a once-weekly amylin analog, is being developed for obesity. The technology exists to create a weekly amylin replacement suitable for type 1 diabetes, but no company has pursued this indication in a dedicated trial as of early 2026.

Can you take a GLP-1 drug and amylin together for type 1 diabetes?

Case reports describe type 1 diabetes patients losing 16-20% of body weight on combined pramlintide and semaglutide therapy. This combination addresses both the amylin deficiency inherent to type 1 diabetes and the appetite-suppressing effects of GLP-1 agonism. No randomized controlled trial has tested this combination specifically in type 1 diabetes.